APP and melanoma: Moreover, high MHC-I expression has been proposed as a predictor of ICB response (Rodig et al., 2018; Liu et al., 2019; Grasso et al., 2020; Shklovskaya et al., 2020), and high expression of MHC-I and other APP genes, including NLRC5 and TAP1, correlates with better survival in patients with melanoma (Figure 5—figure supplement 1A), for whom ICB is a first-line therapy.